on-demand webinar

De-risk pharmaceutical development and scale up with confidence

Discover better designs and optimized processes faster with the digital twin approach

Share

Woman staring at computer screen using Simcenter for modeling

Optimize the entire pharmaceutical product lifecycles with a more comprehensive approach using digital twins from research to production. Integrate simulation tools that can help with mechanistic or hybrid modeling and fluid dynamics to develop optimized process faster. Reduce time with in-silico testing and increase efficiency in pharmaceutical R&D significantly.

<h2>Simulation for Digital Twin</h2><p>Since the 1990s, best-in-class companies in most fields of technology make intensive use of CFD (Computational Fluid Dynamics) and digital twins in product development, scale-up and tech transfer with remarkable success in reducing development costs and time-to-market. However, pharma industry is still slow with adopting process simulation in their development routines. One of the reasons being highly regulatory-driven procedures with a low level of incentives for efficient development.</p><p>According to Aixprocess, a renowned Germany-based process engineering company, with the upcoming use of digital methods, data management and AI-based methods as central elements of lean operations, the application of advanced CFD and particle flow process simulation secures new opportunities in complementing internal process data. Aixprocess can prove that leveraging these technologies results in additional insights to de-risk the scale-up process and technology transfer. </p><h2>Accomplish successful scale-up and technology transfer beyond expectations with CFD</h2><p>Join this webinar hosted by Aixprocess and learn from a real successful use case from pharma API development. The study shows how simulation was used to de-risk the scaling and Tech Transfer of an API crystallization step from lab scale to production scale. With a tailored scaling rule developed in CFD digital twin, the API particle size distribution was kept in a +/- 10% range. The resulting reduction of registration and validation batch numbers in the clinical phase III sums up to savings in cost of goods and analytics of approximately <b>5M EUR</b> and a <b>1-year time-to-market reduction</b> demonstrates the benefits of advanced process simulation with Computational Digital Twins in a joint approach with well-focused lab and pilot scale experiments.</p><h2>In this webinar, you will learn: </h2><ul><li>How to implement simulation technology into API development and formulation procedures</li><li>About the benefits of internal state data availability for development acceleration</li><li>How simulation contributes to LEAN development and operations</li></ul>

Meet the speakers

Aixprocess

Martin Weng

Managing Director

Siemens Digital Industries Software

Peter Jeszencsak

Portfolio Development Executive

Related resources